Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Cardiovascular Protection in Coronary Artery Disease: Mechanistic and Clinical Insights into SGLT2 Inhibitors and GLP-1 Receptor Agonists.

View Full Paper
Ask AI
Bookmark
Share

Authors

NCNicola CosentinoFTFilippo TrombaraMMMonica De Metrio

Discussion

Loading...

Member takes

Overview

Review highlights cardiovascular advantages of SGLT2 inhibitors and GLP-1 receptor agonists in T2DM patients with coronary artery disease.

Key Points

  • SGLT2 inhibitors and GLP-1 receptor agonists improve cardiovascular outcomes in coronary artery disease.
  • Notable benefits include reductions in myocardial infarction risk and overall mortality, especially in patients with type 2 diabetes.
  • Understanding the mechanistic effects and clinical support for these treatments is crucial for managing CAD effectively.
  • Emerging evidence underscores the need for integrating these therapies in treating patients at risk of cardiovascular events.

Cite This Study

Cosentino et al. (2025) studied this question.

synapsesocial.com/papers/68c23b8fb210217d64785488https://doi.org/10.3390/ph18081202
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes2017 · 7,869 citations
  2. 2Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome2015 · 2,383 citations